Psychiatric disorders and cardiovascular diseases during the diagnostic workup of suspected prostate cancer
Menée en Suède à partir de données portant sur 10 996 patients atteints d'un cancer de la prostate récemment diagnostiqué et sur 20 482 hommes subissant une biopsie de la prostate pour une suspicion de cancer, cette étude analyse la présence de troubles psychiatriques et de maladies cardiovasculaires pendant la période précédant le diagnostic ou la biopsie
Background : It is unknown whether the rate of psychiatric disorders and cardiovascular disease is increased during the diagnostic workup of suspected prostate cancer. Methods : We designed a population-based cohort study including 579,992 men living during 2005–2014 in Skåne Sweden according to the Swedish Total Population Register and the Skåne Healthcare Register (SHR). We used the Swedish Cancer Register and the SHR to identify all men with a new diagnosis of prostate cancer (N = 10,996) and all men underwent a prostate biopsy without receiving a cancer diagnosis (biopsy group; N = 20,482) as exposed to a diagnostic workup. Using Poisson regression, we compared the rates of psychiatric disorders and cardiovascular disease during the period before diagnosis or biopsy of exposed men with the corresponding rates of unexposed men. Results : We found an increased rate of psychiatric disorders during the period before diagnosis or biopsy among men with prostate cancer (incidence rate ratio [IRR]=1.87; 95% confidence interval [CI]=1.67 to 2.10) and men in biopsy group (IRR = 2.22; 95% CI = 2.08 to 2.37). The rate of cardiovascular disease was increased during the period before diagnosis or biopsy among men with prostate cancer (IRR = 2.22; 95% CI = 2.12 to 2.32) and men in biopsy group (IRR = 2.56; 95% CI = 2.49 to 2.63). Greater rate increases were noted for a diagnostic workup due to symptoms than due to other reasons. Conclusions : There was an increased risk of psychiatric disorders and cardiovascular disease during the diagnostic workup of suspected prostate cancer, regardless of the final cancer diagnosis.
JNCI Cancer Spectrum 2020